

Addressing Significant Unmet Needs in CNS



Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Marketed
NUPLAZID® (pimavanserin)¹	Parkinson's Disease Psychosis					
DAYBUE™ (trofinetide)²	Rett Syndrome					
Pimavanserin⁴	Negative Symptoms of Schizophrenia					
ACP-204³	Alzheimer's Disease Psychosis					
ASO Programs⁵	SYNGAP1; Rett Syndrome; Undisclosed					
Other Programs	Neuropsychiatric Symptoms					

¹ NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

² DAYBUE (trofinetide) is only approved in the U.S. by the FDA for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. Acadia has an exclusive license to develop and commercialize trofinetide in North America from Neuren Pharmaceuticals.

³ ACP-204 is an investigational agent, and the safety and efficacy of this agents has not been established. There is no guarantee this investigational agent will be filed with or approved by any regulatory agency.

⁴ Safety and efficacy of pimavanserin for the treatment of negative symptoms of schizophrenia have not been established or approved by the FDA.

⁵ Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases.

ASO = Antisense oligonucleotide.

Provided March 10, 2023; contains forward-looking statements; actual results may vary materially; Acadia disclaims any duty to update.